drugset / Trial / NCT04974073

Development of PHY606 as Adjunct Therapy for Anemia Patients

NCT04974073 ↗

Phase 3 Completed 39 enrolled Sheng-Teng Huang
RandomizedParallel-groupDouble-blindBasic science

Summary

Many reasons can cause anemia, decreased RBC production or increased destruction of circulation RBC. The investigators investigate the Danggui Buxue Tang (PHY606) composed of Angelicae Sinensis Radix and Astragali Radix in the fields of genomic and metabolomics in the healthy people and the patiens with anemia.

Timeline

Start
2017-08-22
Primary completion
2017-08-22
Completion
2019-11-18

Drugs

EvaluationDrugModalityDoseRoute
Subject PHY606 Unknown 7.5 g —

Indications